Chemical structure of GHBGamma-hydroxybutyrate powder
Find information on thousands of medical conditions and prescription drugs.


Gamma-hydroxybutyrate (4-hydroxybutanoic acid, C4H8O3) is both a drug and a naturally occurring compound found in the central nervous system as well as in other organs as liver, kidneys, heart and bones. GHB is structurally similar to the ketone body beta-hydroxybutyrate. As a drug it is used most commonly in the form of a chemical salt (Na-GHB or K-GHB). The sodium salt is commercially known as sodium oxybate. more...




The precise function of GHB in body is not clear. It is an immediate precursor to GABA, a neurotransmitter which regulates awakeness, physical activity and sleep. As GABA cannot cross blood-brain barrier, GHB obtained from food may be used for converting to GABA. GHB prevents cells from oxygen starvation, which might explain presence of the compound in vital organs. GHB was also found to have neuroprotective capabilities.


It has been used as a general anesthetic, and a hypnotic in the treatment of insomnia. GHB has also been used to treat clinical depression, and improve athletic performance. In the United States, the Food and Drug Administration permits the use of GHB under the trade name Xyrem to reduce the number of cataplexy attacks in patients with narcolepsy.


GHB is an intoxicant. It may be known as G, Liquid X, Liquid E. It is less commonly known as GBH, Gamma-oh, Georgia Homeboy, Blue Verve, Gamma-G, Qi, scoop, goop, Grievous Bodily Harm, or Get Hospitalised Bitch.

Its potential for use as a date rape drug in the 1990s led to it being placed in the US on Schedule I of the Controlled Substances Act in March, 2000. On March 20, 2001, the Commission on Narcotic Drugs placed GHB in Schedule IV of the 1971 Convention on Psychotropic Substances. In the UK it was made a class C drug in June 2003.

The sodium salt of GHB has a thin, very salty, chemical taste. At low doses, GHB can cause a state of euphoria, increased sociality and intoxication. This kind of use is particularly common at rave parties. At higher doses, GHB may induce nausea, dizziness, drowsiness, visual disturbances, depressed breathing, amnesia and unconsciousness. The effects of GHB can last from 1.5 to 3 hours.

Some chemicals convert to GHB in the stomach and blood. GBL, or gamma-butyrolactone, is one such precursor. It is 1,6 times more potent than GHB, so 1ml of GBL is equivalent to 0,4g of GHB. GBL has also a shorter onset and is longer acting than GHB. GBL has an extremely bad taste and is also known to irritate innards and skin.

Other precursors include 1,4-butanediol. There may be additional toxicity concerns with these precursors.

Mode of action

The action of GHB has yet to be fully elucidated. GHB clearly has at least two sites of action, stimulating the newly characterized and aptly named "GHB receptor" as well as the GABAB. GHB, if it is indeed a neurotransmitter, will only reach concentrations high enough to act at the GHB receptor, as it only has weak affinity fo the GABAB. However, during recreational usage, GHB can reach very high concentrations in the brain, relative to basal levels, and can act at the GABAB receptor . GHBs action at the GABAB is probably responsible for its sedative effects. GHB-mediated GABAB receptor stimulation inhibits dopamine release as well as causes the release of natural sedative neurosteroids (like all other GABAB agonists e.g. Baclofen). In animals GHBs sedative effects can be stopped by GABAB antagonists (blockers).


[List your site here Free!]

New & approved: Zelnorm * Xyrem. : An article from: Internal Medicine News $5.95 FDA Approval of 'Club Drug' for Cataplexy Is Imminent.(sodium oxybate (Xyrem) therapy to be restricted) : An article from: Clinical Psychiatry News $5.95
FDA ACCEPTS XYREM SNDA FOR REVIEW. : An article from: Biotech Business $5.95 ORPHAN MEDICAL GETS POSITIVE XYREM CLINICAL RESULTS. : An article from: Biotech Business $5.95
New and approved: Zelnorm * Xyrem. (Rx).(irritable bowel syndrome) : An article from: Family Practice News $5.95 ORPHAN MEDICAL SUBMITS XYREM SNDA TO FDA. : An article from: Biotech Business $5.95
Sodium Oxybate Works for Cataplexy, but Has Abuse Potential. : An article from: Internal Medicine News $5.95

Xyrem - New & Approved
(sodium oxybate or [gamma]- hydroxybutyrate, Orphan Medical) A central nervous system depressant for treating cataplexy in people with narcolepsy.
Xyrem approved for muscle problems in narcolepsy - Updates
The FDA recently approved Xyrem (sodium oxybate or gamma hydroxybutyrate, also known as GHB) for treating a small population of people with narcolepsy ...
Xyrem(R) is Launched in Germany for the Treatment of Cataplexy in Adults with Narcolepsy
Brussels, Belgium - December 8, 2005: UCB announced today that Xyrem® (sodium oxybate) oral solution is now available in Germany for the treatment ...
Jazz Pharmaceuticals Announces European Commission Marketing Approval of Xyrem
UCB Launches Xyrem in Germany PALO ALTO, Calif., Dec. 8 /PRNewswire/ -- Jazz Pharmaceuticals, Inc. announced today that the European Commission has ...
Xyrem® Receives FDA Approval for the Treatment of Excessive Daytime Sleepiness in Patients With Narcolepsy
PALO ALTO, Calif., Nov. 22 /PRNewswire/ -- Jazz Pharmaceuticals announced today that Xyrem(R) (sodium oxybate) oral solution has been approved for marketing by the U.S. Food and Drug Administratio
Study Finds That Xyrem® Relieves Pain and Improves Functioning in Patients Suffering From Fibromyalgia
Data presented today at the American College of Rheumatology Meeting PALO ALTO, Calif., Nov. 17 /PRNewswire/ -- Patients with fibromyalgia syndrome ...
Orphan Medical Issues Xyrem Prescriptions Update
MINNEAPOLIS -- ORPHAN MEDICAL, INC. (Nasdaq:ORPH) announced that the total number of Xyrem(R) (sodium oxybate) oral solution prescriptions filled in ...
FDA Accepts Xyrem sNDA for Review, User Fee Deadline Set for November 18, 2005, Company Receives $1 Million Payment from UCB Pharma Limited
MINNEAPOLIS -- Nearly Two-Thirds of Patients in Fibromyalgia Trial Have Completed the Protocol Orphan Medical, Inc. (Nasdaq:ORPH) announced today that the Food and Drug Administration (FDA) has a

Home Contact Resources Exchange Links ebay